|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Cytovax Biotechnologies Inc., of Edmonton, Alberta, enrolled the last subject in the Phase I trial of its lead product, Cytovaxine, a peptide vaccine designed to prevent infections caused by Pseudomonas aeruginosa. In the randomized, double-blinded study, designed to investigate the product's safety, 35 individuals were enrolled and will receive one of three escalating dose levels of Cytovaxine or a control vaccine. A study-entry, six-week and five-month injection schedule will be employed. A six-week safety evaluation prior to dose escalation also was included.
MGI Pharma Inc., of Minneapolis, and Helsinn Healthcare SA, of Lugano, Switzerland, submitted to the ...